Zevra Therapeutics Inc (ZVRA)
9.585
+0.46
(+4.98%)
USD |
NASDAQ |
Nov 22, 16:00
9.64
+0.06
(+0.57%)
After-Hours: 20:00
Zevra Therapeutics Free Cash Flow: -69.57M for Sept. 30, 2024
Free Cash Flow Chart
Historical Free Cash Flow Data
| Date | Value |
|---|---|
| September 30, 2024 | -69.57M |
| June 30, 2024 | -56.06M |
| March 31, 2024 | -45.66M |
| December 31, 2023 | -33.83M |
| September 30, 2023 | -22.10M |
| June 30, 2023 | -23.92M |
| March 31, 2023 | -19.32M |
| December 31, 2022 | -18.81M |
| September 30, 2022 | -15.18M |
| June 30, 2022 | -11.29M |
| March 31, 2022 | 9.354M |
| December 31, 2021 | 10.34M |
| September 30, 2021 | 10.12M |
| June 30, 2021 | 11.80M |
| March 31, 2021 | -2.525M |
| December 31, 2020 | -1.972M |
| September 30, 2020 | -3.99M |
| June 30, 2020 | -5.172M |
| March 31, 2020 | -14.71M |
| December 31, 2019 | -23.76M |
| Date | Value |
|---|---|
| September 30, 2019 | -35.67M |
| June 30, 2019 | -49.40M |
| March 31, 2019 | -51.21M |
| December 31, 2018 | -54.22M |
| September 30, 2018 | -46.15M |
| June 30, 2018 | -40.40M |
| March 31, 2018 | -37.76M |
| December 31, 2017 | -33.28M |
| September 30, 2017 | -35.79M |
| June 30, 2017 | -34.19M |
| March 31, 2017 | -36.10M |
| December 31, 2016 | -30.42M |
| September 30, 2016 | -27.41M |
| June 30, 2016 | -23.47M |
| March 31, 2016 | -20.31M |
| December 31, 2015 | -20.40M |
| September 30, 2015 | -20.95M |
| June 30, 2015 | -20.18M |
| March 31, 2015 | -17.85M |
| December 31, 2014 | -14.72M |
Free Cash Flow Range, Past 5 Years
-69.57M
Minimum
Sep 2024
11.80M
Maximum
Jun 2021
-16.31M
Average
-14.95M
Median
Free Cash Flow Benchmarks
| Johnson & Johnson | 19.02B |
| Ionis Pharmaceuticals Inc | -374.21M |
| Vanda Pharmaceuticals Inc | -18.20M |
| BioCardia Inc | -7.309M |
| Xeris Biopharma Holdings Inc | -32.26M |
Free Cash Flow Related Metrics
| Cash from Operations (Quarterly) | -18.14M |
| Cash from Investing (Quarterly) | -31.35M |
| Cash from Financing (Quarterly) | 64.76M |
| Free Cash Flow Per Share (Quarterly) | -0.3794 |
| Free Cash Flow to Equity (Quarterly) | -18.72M |
| Free Cash Flow to Firm (Quarterly) | -16.88M |
| Free Cash Flow Yield | -17.06% |